The evidence thing

Annals of Vascular Surgery

Volumn 18, Issue 3, 2004, Pages 265-270

  Berguer, Ramon ^a,b,c  

^a Wayne State University ^*

^b WAYNE STATE UNIVERSITY   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HEALTH CARE PLANNING; HUMAN; LANGUAGE; MEDICAL LITERATURE; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SYSTEMATIC REVIEW;

EID: 2542447345     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10016-004-0044-3     Document Type: Note

References (35)

1. Colyer H, Kamath P. Evidence-based practice. A philosophical and political analysis: some matters for considerations by professional practitioners. J. Adv. Nurs. 1999;29: 188-193.
2. Sackett DL, Rosenberg WMC, Muir Gray JM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. B.M.J. 1996;312:71-72.
3. Benson K, Hartz AJ. A comparison of observational studies and randomized controlled trials. N. Engl. J. Med. 2000; 342:1878-1886.
4. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 2000;342:1887-1892.
5. Sundt T.. Was the international randomized trial of extracranial-intracranial arterial bypass representative of the population at risk?. N. Engl. J. Med. 1987;316:814-816.
6. Gebski VJ, Beller EM, Keech AC. Trails on trial. Med. J. Aust. 2001;175:272-274.
7. Eysenck HJ. Meta-analysis and its problems. B.M.J. 1994; 309:789-792.
8. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet 2000; 356:635-638.
9. Cohn JN. Anti-intellectualism in clinical cardiovascular medicine. J. Cardiac Failure 2000;6:287-289.
10. Tonelli M. The philosophical limits of evidence-based medicine. Acad. Med. 1998;73:1234-1240.
11. The Executive Committee for the Asymptomatic Carotid Atherosclerosis study endarterectomy for asymptomatic carotid stenosis. J.A.M.A. 1995;273:1421-1428.
12. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Steering Committee. North American Symptomatic Carotid Endarterectomy Trial: methods, patient characteristics and prognosis. Stroke 1991;22:711-720.
13. European Carotid Surgery Trialists Collaborative GroupMRC European Carotid Surgery Trial: interim results for patients with severe (70-99%) or with mild (0-29%) carotid stenosis, Lancet 1991;337:1235-1243.
14. Dixon S, Pais SO, Raviola C, et al. Natural history of non-stenotic asymptomatic ulcerative lesions of the carotid artery. Arch. Surg. 1982;117:1493.
15. Geroulakos G, Domjan J, Nicolaides A, et al. Ultrasonic carotid artery plaque structure and the risk of cerebral infarction on computed tomography. J. Vasc. Surg. 1994;20:263-266.
16. Imparato AM, Riles TS, Mintzer R, Baumann FG. The importance of hemorrhage in the relationship between gross morphologic characteristics and cerebral symptoms in 376 carotid artery plaques. Ann. Surg. 1982;2:195-203.
17. Biasi GM. Incidence of neurologic complications following carotid artery stenting correlated to the characteristics of the plaque composition: preliminary results of the ICAROS study. 27th International Stroke Conference 2002. Stroke 2002;33:342.
18. Goodman S. Towards evidence-based medical statistics. 1: The p-value fallacy. Ann. Intern. Med. 1999;130:995-1004.
19. Goodman S. Towards evidence-based medical statistics. 2: The Bayes factor. Ann. Intern. Med. 1999;130:1005-1013.
20. Vandenbroucke JP. In defense of case reports and case series. Ann. Intern. Med. 2001;134:330-334.
21. Vandenbroucke JP. Case reports in an evidence-based world. J. R. Soc. Med. 1999;2:159-163.
22. Sackett DL, Hoey J. Why randomized controlled trials fail but needn't: a new series is launched. C.M.A.J. 2000; 162:1301-1302.
23. Davidoff F, Deangelis CD, Drazen JM. Conflict of interest-sponsorship, authorship, and accountability. N. Engl. J. Med. 2001;345:825-827.
24. Rochon PA, Qurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of non-steroidal anti-inflammatory drugs in the treatment of arthritis. Arch. Intern. Med. 1994;154:157-163.
25. Davidson R. Source of funding and outcome of clinical trials. J. Gen. Intern. Med. 1986;1:155-158.
26. Stelfox HT, Chua G, O"Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N. Engl. J. Med. 1998;338:101-106.
27. Weatherall D.. Academia and industry: increasingly uneasy bedfellows. Lancet 2000;355:1574.
28. Freidberg M, Saffran B, Stinson TJ, Nelson TJ, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. J.A.M.A. 1999;282:1453-1457.
29. Fernandez-Armesto F. Truth. New York: St. Martins Press, 1997.
30. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam. Practice 2001;18:565-568.
31. Feinstein AR, Horwitz RI. Problems in the "evidence" of "evidence-based medicine.". Am. J. Med. .: 103:529-535.
32. Tonelli MR, Callahan TC. Why alternative medicine cannot be evidence-based. Acad. Med. 2001;76:1213-1220.
33. Straus SE. Evidence-based medicine: a commentary on common criticisms. C.M.A.J. 2000;163:837-841.
34. Rees J. Evidence-based medicine: the epistemology that isn't. J. Am. Acad. Dermatol. 2000;43:727-729.
35. Tanenbaum SJ. What physicians know. N. Engl. J. Med. 1993;329:1268-1270.